Veradermics
MANE
110.95
+1.99
+1.83%
Veradermics
US · MANE
#2148 by market cap
Listed 2026
110.95
+1.99
+1.83%
Live - 5344 symbols - heartbeat 259s ago
· 2026-10-08 07:00
Pre-market
111.10
+0.14%
After-hours
110.95
0.00%
Overnight
110.95
0.00%
- Market cap
- 4.64B
- P/E (TTM)i
- -44.45
- P/Bi
- 5.70
- EPSi
- -2.23
- Div yieldi
- 0.00%
- 52W posi
- 80%
Reader sentiment
Are you bullish or bearish on MANE?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 3 years
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | -- | -- | -- |
| Gross profit | -- | -- | -- |
| Selling & admin expenses | 2.35M | 3.50M | 10.28M |
| Research & development | 14.97M | 23.28M | 62.07M |
| Operating profit | -17.32M | -26.38M | -71.56M |
| Pretax profit | -16.49M | -26.49M | -70.00M |
| Tax | 0 | 0 | 0 |
| Net profit | -16.49M | -26.49M | -70.00M |
| Basic EPS | -2 | -1 | -2 |
| Diluted EPS | -1.51 | -1.37 | -2.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.47M | 1.74M | 2.25M | 4.82M | 8.94M | 10.95M |
| Research & development | 11.45M | 14.33M | 18.10M | 18.19M | 20.93M | 18.61M |
| Operating profit | -12.88M | -16.07M | -19.82M | -22.75M | -29.71M | -29.55M |
| Pretax profit | -12.40M | -15.65M | -20.10M | -21.85M | -27.23M | -23.50M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -12.40M | -15.65M | -20.10M | -21.85M | -27.23M | -23.50M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.73 | -0.51 | -0.64 | -0.62 | -1.32 | -0.58 |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 17.56M | 55.54M | 152.49M |
| Cash & ST investments | 16.30M | 53.08M | 141.86M |
| Inventory | -- | -- | -- |
| Total assets | 17.56M | 55.54M | 152.62M |
| Total current liabilities | 3.05M | 4.72M | 9.15M |
| Short-term debt | -- | -- | -- |
| Long-term debt | 786.00K | -- | -- |
| Total liabilities | 39,804,000.00 | 104,015,000.00 | 273,633,000.00 |
| Total equity | -22.24M | -48.48M | -121.01M |
| Retained earnings | -22.74M | -49.23M | -123.42M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 18.71M | 152.49M | 397.07M | 824.75M |
| Cash & ST investments | -- | -- | 15.14M | 141.86M | 390.80M | 819.89M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 18.80M | 152.62M | 397.36M | 825.74M |
| Total current liabilities | -- | -- | 5.69M | 9.15M | 6.72M | 11.69M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 114,812,000.00 | 273,633,000.00 | 6,716,000.00 | 12,122,000.00 |
| Total equity | -- | -- | -96.02M | -121.01M | 390.64M | 813.61M |
| Retained earnings | -- | -- | -97.38M | -123.42M | -150.65M | -174.16M |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -13.51M | -23.69M | -71.60M |
| Depreciation & amortization | -- | -- | -- |
| Free cash flow | -13.51M | -23.69M | -71.63M |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- |
| Ending cash balance | 16.30M | 53.08M | 21.77M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.32M | -15.64M | -19.01M | -23.63M | -21.17M | -14.49M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -13.34M | -15.64M | -19.01M | -23.63M | -21.17M | -14.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 269.10M | 414.34M |
| Ending cash balance | 32.44M | 8.60M | 5.66M | 21.77M | 168.41M | 319.33M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | -- | -- | -- |
| ROA %i | -93.90 | -74.70 | -80.11 |
| ROIC %i | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | -- | -- | -- |
| FCF / sales %i | -- | -- | -- |
| Current ratioi | 5.75 | 11.77 | 16.66 |
| Quick ratioi | 5.34 | 11.54 | 15.64 |
| Debt / assetsi | 4.48 | 0.00 | 0.00 |
| LT debt / equityi | -- | -- | -- |
| Interest coveragei | -457.06 | -44.28 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -25.29 | -12.82 |
| ROA %i | -- | -- | -327.93 | -80.11 | -24.86 | -12.63 |
| ROIC %i | -- | -- | -- | -- | -26.20 | -13.83 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 3.29 | 16.66 | 59.12 | 70.53 |
| Quick ratioi | -- | -- | 2.88 | 15.64 | 58.43 | 70.25 |
| Debt / assetsi | -- | -- | 0.09 | 0.00 | 0.00 | 0.05 |
| LT debt / equityi | -- | -- | -- | -- | -- | 0.05 |
| Interest coveragei | -- | -- | -183.27 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:00:21 · For reference only, not investment advice and not tailored to your situation.